Europäischer Non-Hodgkin-Lymphom-Diagnostikmarkt Größe & Umfang Bis 2030

Europe Non Hodgkin Lymphoma Diagnostics Market

Marktgröße in Milliarden USD

CAGR : 8.20 %

Prognosezeitraum	2024 –2030
Marktgröße (Basisjahr)	MILLIONEN USD Anfrage
Marktgröße (Prognosejahr)	MILLIONEN USD Antrag auf Freischaltung
CAGR	8.20 %
Wichtige Marktteilnehmer	Dummy1 Dummy2 Dummy3 Dummy4 Dummy5 Anfrage zur Freischaltung

>Europa Non-Hodgkin-Lymphom-Diagnostik-Markt, nach Testtyp (Bildgebung, Biopsie, Immunhistochemie, Biomarker, genetischer Test , Zytogenetik, Lumbalpunktion, Bluttest, Zytochemie und andere), Krebsstadium (Stadium IV, Stadium III, Stadium II, Stadium I und Stadium 0), Tumortyp (aggressive Lymphome und indolente Lymphome), Produkt (instrumentenbasierte Produkte, plattformbasierte Produkte, Kits und Reagenzien und andere Verbrauchsmaterialien), Technologie (Fluoreszenz-In-situ-Hybridisierung, Sequenzierung der nächsten Generation, Fluorimmunoassay, vergleichende genomische Hybridisierung, Immunhistochemie und andere), Anwendung (Screening, Diagnose und Vorhersage, Prognose und Forschung), Endbenutzer (Krankenhäuser, Diagnosezentren, Krebsforschungszentren, akademische Institute, ambulante chirurgische Zentren und andere), Vertriebskanal (direkte Ausschreibung, Einzelhandelsverkauf und andere) - Branchentrends und Prognose für 2030.

Europa: Marktanalyse und Einblicke in die Non-Hodgkin-Lymphom-Diagnostik

Das zunehmende Bewusstsein für das Non-Hodgkin-Lymphom in Europa hat die Nachfrage auf diesem Markt erhöht. Die steigenden Gesundheitsausgaben für bessere Gesundheitsdienste tragen ebenfalls zum Wachstum des Marktes bei. Die wichtigsten Marktteilnehmer konzentrieren sich in dieser entscheidenden Phase auf die Einführung und Zulassung verschiedener Dienste. Darüber hinaus trägt auch die Zunahme verbesserter Diagnoseverfahren und -techniken zur steigenden Nachfrage nach Diagnosetests für das Non-Hodgkin-Lymphom bei.

Der europäische Markt für Non-Hodgkin-Lymphomdiagnostik dürfte im Prognosejahr aufgrund der Zunahme der Marktteilnehmer und der Verfügbarkeit fortschrittlicher Dienste wachsen. Darüber hinaus betreiben die Hersteller Forschungs- und Entwicklungsaktivitäten, um neue Dienste auf den Markt zu bringen. Die zunehmende Forschung im Bereich der Diagnose und Entwicklung von Non-Hodgkin-Lymphomen fördert das Marktwachstum weiter. Schwierigkeiten bei den Screeningtechniken für Non-Hodgkin-Lymphome könnten jedoch das Wachstum des europäischen Marktes für Non-Hodgkin-Lymphomdiagnostik im Prognosezeitraum behindern.

Steigende Gesundheitsausgaben für die Diagnose und Behandlung von Krebs dürften dem Markt Chancen eröffnen, die Behandlung zu verbessern. Die hohen Testkosten und die strengen Vorschriften und Standards für die Zulassung und Vermarktung von Krebsdiagnostikprodukten könnten das Marktwachstum jedoch bremsen.

Der europäische Markt für Non-Hodgkin-Lymphomdiagnostik ist unterstützend und zielt darauf ab, das Fortschreiten der Krankheit zu verlangsamen. Data Bridge Market Research analysiert, dass der europäische Markt für Non-Hodgkin-Lymphomdiagnostik im Prognosezeitraum von 2023 bis 2030 mit einer durchschnittlichen jährlichen Wachstumsrate von 8,2 % wachsen wird.

Berichtsmetrik	Details
Prognosezeitraum	2023 bis 2030
Basisjahr	2022
Historische Jahre	2021 (Anpassbar auf 2015 – 2020)
Quantitative Einheiten	Umsatz in Millionen USD und Preise in USD
Abgedeckte Segmente	Testtyp (Bildgebung, Biopsie, Immunhistochemie, Biomarker, Gentest, Zytogenetik, Lumbalpunktion, Bluttest, Zytochemie und andere), Krebsstadium (Stadium IV, Stadium III, Stadium II, Stadium I und Stadium 0), Tumortyp (aggressive Lymphome und indolente Lymphome), Produkt (instrumentenbasierte Produkte, plattformbasierte Produkte, Kits und Reagenzien und andere Verbrauchsmaterialien), Technologie (Fluoreszenz-in-situ-Hybridisierung, Sequenzierung der nächsten Generation, Fluorimmunoassay, vergleichende genomische Hybridisierung, Immunhistochemie und andere), Anwendung (Screening, Diagnose und Vorhersage, Prognose und Forschung), Endbenutzer (Krankenhäuser, Diagnosezentren, Krebsforschungszentren, akademische Institute, ambulante chirurgische Zentren und andere), Vertriebskanal (direkte Ausschreibung, Einzelhandelsverkauf und andere)
Abgedeckte Länder	Deutschland, Großbritannien, Frankreich, Italien, Spanien, Russland, Niederlande, Schweiz, Belgien, Türkei und Rest von Europa
Abgedeckte Marktteilnehmer	CANON MEDICAL SYSTEMS CORPORATION (Präfektur Tochigi, Japan), Koninklijke Philips NV (Amsterdam, Niederlande), Siemens Healthcare GmbH (Erlangen, Deutschland), Danaher (Washington, USA), Bio-Rad Laboratories, Inc (Kalifornien, USA), General Electric Company (Massachusetts, USA), Sysmex Corporation (Hyogo, Japan), Grail (Kalifornien, USA), F. Hoffmann-La Roche (Basel, Schweiz), Neusoft Corporation (Shenyang, China), Agilent Technologies, Inc. (Kalifornien, USA), NeoGenomics Laboratories (Florida, USA), Hologic, Inc (Massachusetts, USA), Integrated DNA Technologies, Inc., CENTOGENE NV (Rostock, Deutschland), Merit Medical Systems (Utah, USA), Invitae Corporation (Kalifornien, USA), PerkinElmer Inc. (Massachusetts, USA), QIAGEN (Kalifornien, USA) und GeneDx. LLC (Connecticut, USA) unter anderem.

Marktdefinition

Krebs beginnt in den Lymphen und tritt am häufigsten bei Rauchern auf. Es gibt zwei Haupttypen von Non-Hodgkin-Lymphomen: aggressives Non-Hodgkin-Lymphom und indolentes Non-Hodgkin-Lymphom. Zu den Ursachen von Non-Hodgkin-Lymphomen zählen Rauchen, Passivrauchen, Kontakt mit bestimmten Giftstoffen und familiäre Vorbelastung.

Zu den Symptomen gehören Husten (oft mit Blut), Brustschmerzen, Keuchen und Gewichtsverlust. Diese Symptome treten oft erst auf, wenn der Krebs fortgeschritten ist. Die Behandlungen variieren, können aber Operation, Chemotherapie, Strahlentherapie, gezielte medikamentöse Therapie und Immuntherapie umfassen.

Europa Non-Hodgkin-Lymphom-Diagnostik Marktdynamik

In diesem Abschnitt geht es um das Verständnis der Markttreiber, Vorteile, Chancen, Einschränkungen und Herausforderungen. All dies wird im Folgenden ausführlich erläutert:

Erhöhter Anstieg der Prävalenz von Non-Hodgkin-Lymphomen

Lymphom ist der allgemeine Name für viele verwandte Krebsarten, die aus einer Art weißer Blutkörperchen namens „Lymphozyten“ entstehen. Lymphom wird in zwei Hauptkategorien unterteilt: Hodgkin-Lymphom (HL) und Non-Hodgkin-Lymphom (NHL). Non-Hodgkin-Lymphom ist eine allgemeine Kategorie von Lymphomen. Es gibt viele Unterarten, die in diese Kategorie fallen. Diffuses großzelliges B-Zell-Lymphom und follikuläres Lymphom gehören zu den häufigsten Unterarten. Die Zahl der Lymphomkrebsfälle nimmt weltweit zu. Non-Hodgkin-Lymphom (NHL) ist eine der häufigsten Krebsarten in den Vereinigten Staaten und macht etwa 4 % aller Krebserkrankungen aus.

Die Wahrscheinlichkeit, dass ein Mann im Laufe seines Lebens an NHL erkrankt, liegt bei etwa 1 zu 43; bei einer Frau beträgt das Risiko etwa 1 zu 53. Im Jahr 2020 wurden laut der Internationalen Agentur für Krebsforschung der Weltgesundheitsorganisation (WHO) weltweit schätzungsweise 544.352 Menschen mit Non-Hodgkin-Lymphom diagnostiziert.

Steigendes Bewusstsein für Non-Hodgkin-Lymphom

Die Aufklärungskampagne zum Non-Hodgkin-Lymphom ist eine Gelegenheit, das Wissen über diese Krankheiten zu erweitern und die Forschung zu ihren Ursachen, ihrer Vorbeugung, Diagnose, Behandlung und Überlebenschancen in den Vordergrund zu rücken. Ziel ist es, Menschen zu helfen, die von Lymphomen betroffen sind, und gesunde Gewohnheiten zu fördern.

Lymphome sind die fünfthäufigste Krebsart weltweit. Laut Bericht der Weltgesundheitsorganisation hat Asien mit 241.270 Patienten in den letzten 5 Jahren die höchste Inzidenzrate. Außerdem sind 7,4 % aller Krebstodesfälle in Asien auf das Non-Hodgkin-Lymphom zurückzuführen. Die Sterberate steigt jedes Jahr sehr langsam an.

Jedes Jahr werden weltweit mehrere Aufklärungskampagnen, Webinare und Konferenzen geplant, um die Menschen über das Non-Hodgkin-Lymphom zu informieren. Verschiedene Organisationen übernehmen dabei die Führung. Dies dürfte das Wachstum des europäischen Marktes für Non-Hodgkin-Lymphom-Diagnostik vorantreiben.

Mangel an ausgebildetem und qualifiziertem medizinischem Fachpersonal

Die Dichte des gesamten Gesundheitspersonals wird auf 29 pro 10.000 Einwohner geschätzt, aber nur 16 pro 10.000 ausgebildete Arbeitskräfte. Der Bedarf an qualifizierten und zertifizierten Fachkräften ist eine große Einschränkung für den europäischen Markt für Non-Hodgkin-Lymphom-Diagnostik. Die Nachfrage nach Fluoreszenz-in-situ-Hybridisierung steigt aufgrund der zunehmenden Fälle von Krebserkrankungen und genetischen Anomalien, aber die geringere Zahl an qualifizierten Fachkräften dürfte das Wachstum des Marktes behindern.

Die Fähigkeit eines qualifizierten Arztes, zahlreiche Tests durchzuführen, ist für das Wachstum des Gesundheits- und Medizinsektors von entscheidender Bedeutung. Das Hauptziel eines professionellen Teams besteht darin, zu garantieren, dass jedes lebensrettende medizinische Gerät auch dann noch effektiv funktioniert, wenn es am dringendsten benötigt wird. Der Techniker muss über die entsprechende Ausbildung und Zertifizierung der entsprechenden Hersteller und Behörden verfügen.

Techniker haben mit technischen Ausbildungslücken zu kämpfen, die sich auf Probleme bei der sicheren Anpassung fortgeschrittener Methoden zur effizienten Durchführung von Verfahren beziehen. Für die Diagnose von Lymphomen besteht ein hoher Bedarf an qualifizierten Fachkräften für Methodenentwicklung, Validierung, Betrieb und Fehlerbehebung.

Strenge Vorschriften und Richtlinien für verschiedene Behandlungen und Diagnosen

Der Verkauf von Medizinprodukten oder Medikamenten in solchen Ländern kann mit erheblichen finanziellen Aufwendungen verbunden sein und Monate oder Jahre dauern. Wenn diese Einschränkungen nicht verstanden oder berücksichtigt werden, können Verzögerungen die Erfolgsaussichten in einem hart umkämpften Markt ernsthaft gefährden. Ihre Zulassung und Vermarktung in zahlreichen Regionen der Welt erfordert jedoch die Einhaltung strenger regulatorischer Standards und die Akzeptanz durch verschiedene Aufsichtsbehörden.

Die Unternehmen müssen die Produktspezifikationen sorgfältig prüfen, bevor sie sie gemäß den Protokollen der Food and Drug Administration (FDA) kategorisieren. Die Einrichtung von Arzneimittelentdeckungs- und -entwicklungsprogrammen in akademischen, gemeinnützigen und anderen biowissenschaftlichen Forschungsunternehmen erfordert sorgfältige Planung. Jedes Land hat seine eigene Regulierungsbehörde, und die Regulierungsbehörden haben nur eine minimale Aufsicht über Arzneimittelentdeckungsstudien, stellen jedoch bestimmte Anforderungen und eine klare Dokumentation, um Meilensteine während dieses Prozesses zu erreichen. Der Regulierungsrahmen zielt darauf ab, den Zugang für bessere Qualität zu verbessern und Leitlinien zur Stärkung der Regulierungskontrollen bereitzustellen.

Auswirkungen von COVID-19 auf den europäischen Markt für Non-Hodgkin-Lymphomdiagnostik

Die hohe Belastung der Gesundheitssysteme durch COVID-19 weltweit hat bei medizinischen Onkologen Bedenken hinsichtlich der Auswirkungen von COVID-19 auf die Diagnose und Behandlung von Non-Hodgkin-Lymphomen geweckt. In dieser retrospektiven Kohortenstudie haben wir die Auswirkungen von COVID-19 auf die Diagnose und Behandlung von Non-Hodgkin-Lymphomen vor und nach der COVID-19-Ära untersucht. Während der Pandemie gingen die Neudiagnosen von Non-Hodgkin-Lymphomen mit leicht fortgeschritteneren Krankheitsstadien zurück, und es gab einen signifikanten Anstieg der Radiochirurgie als erste definitive Behandlung sowie einen Rückgang sowohl der systemischen Behandlung als auch der Operation im Vergleich zur Zeit vor COVID-19. Im Vergleich zur Zeit vor COVID-19 gab es während der Pandemie keine signifikante Verzögerung beim Beginn der Chemotherapie und Strahlenbehandlung.

Während der Pandemie beobachteten wir jedoch eine Verzögerung bei der Operation von Non-Hodgkin-Lymphomen. COVID-19 scheint erhebliche Auswirkungen auf die Diagnosen und Behandlungsmuster von Non-Hodgkin-Lymphom-Patienten in unserem Non-Hodgkin-Lymphom-Zentrum gehabt zu haben. Viele Onkologen sind besorgt, dass die Zahl der neu diagnostizierten Non-Hodgkin-Lymphom-Patienten im kommenden Jahr steigen wird. Diese Forschung ist noch im Gange, und es werden weitere Informationen gesammelt und analysiert, um die Gesamtauswirkungen der COVID-19-Pandemie auf unsere Non-Hodgkin-Lymphom-Patientenpopulation besser zu verstehen.

Jüngste Entwicklung

Im November 2022 gab Danaher bekannt, dass es eine strategische Partnerschaft mit der Duke University eingegangen ist, um seinen ersten Danaher Beacon für Gentherapie-Innovation zu gründen. Das Programm investiert in Produktinnovationen, um externe F&E-Strategien mit Schwerpunkt auf genomischen Medikamenten, Präzisionsdiagnostik, Bioproduktion der nächsten Generation, menschlichen Systemen und Datenwissenschaften voranzutreiben.
Im August 2022 übernahm Bio-Rad Laboratories Inc. Curiosity Diagnostics, einen in Polen ansässigen Entwickler innovativer Technologielösungen für den medizinischen Diagnostik- und Gesundheitsmarkt. Dies hat dem Unternehmen geholfen, sein Produktportfolio und seine europäische Marktpräsenz zu erweitern.

Europa Non-Hodgkin-Lymphom-Diagnostik Marktsegmentierung

Der europäische Markt für Non-Hodgkin-Lymphom-Diagnostik ist in acht wichtige Segmente unterteilt, die auf Testtyp, Krebsstadium, Tumortyp, Produkt, Technologie, Anwendung, Endbenutzern und Vertriebskanal basieren. Das Wachstum zwischen den Segmenten hilft Ihnen bei der Analyse von Nischenwachstumsbereichen und Strategien zur Marktansprache sowie bei der Bestimmung Ihrer wichtigsten Anwendungsbereiche und der Unterschiede in Ihren Zielmärkten.

NACH TESTTYP

Bildgebung
Biopsie
Immunhistochemie
Biomarker-Test
Genetischer Test
Zytogenetik
Lumbalpunktion (Spinalpunktion)
Blutprobe
Zytochemie
Sonstiges

NACH KREBSSTADIUM

Etappe 0
Stufe I
Stufe II
Stufe III
Stadium IV

NACH TUMORTYP

Aggressive Lymphome
Indolente Lymphome

NACH PRODUKT

Instrumentenbasierte Produkte
Plattformbasierte Produkte
Kits und Reagenzien
Andere Verbrauchsmaterialien

NACH TECHNOLOGIE

Fluoreszenz-In-Situ-Hybridisierung
Sequenzierung der nächsten Generation
Fluorimmunoassay
Vergleichende genomische Hybridisierung
Immunhistochemisch
Sonstiges

NACH ANWENDUNG

Vorsorgeuntersuchungen
Diagnostisch und prädiktiv
Prognose
Forschung

DURCH ENDBENUTZER

Krankenhäuser
Diagnostikzentren
Krebsforschungszentren
Akademische Institute
Ambulante Chirurgische Zentren
Sonstiges

NACH VERTRIEBSKANAL

Direkte Ausschreibung
Einzelhandelsumsätze
Sonstiges

Europa: Regionale Analyse/Einblicke zum Non-Hodgkin-Lymphom-Diagnostikmarkt

Der europäische Markt für Non-Hodgkin-Lymphom-Diagnostik wird analysiert und es werden Erkenntnisse und Trends zur Marktgröße nach Testtyp, Krebsstadium, Tumorart, Produkt, Technologie, Anwendung, Endbenutzer und Vertriebskanal wie oben angegeben bereitgestellt.

Die im Bericht zur Diagnostik von Non-Hodgkin-Lymphomen abgedeckten Länder sind Deutschland, Frankreich, Großbritannien, Italien, Spanien, die Niederlande, Russland, die Schweiz, die Türkei, Österreich, Norwegen, Ungarn, Litauen, Irland, Polen und das übrige Europa.

Deutschland dominiert den europäischen Markt für Non-Hodgkin-Lymphom-Diagnostik aufgrund der zunehmenden Technologie und Zuverlässigkeit der Gesundheitsdienste, die auch Infotainment-Dienste anbieten.

Der Länderabschnitt des Berichts enthält auch individuelle marktbeeinflussende Faktoren und Änderungen der Marktregulierung, die die aktuellen und zukünftigen Trends des Marktes beeinflussen. Datenpunkte wie Downstream- und Upstream-Wertschöpfungskettenanalyse, technische Trends und Porters Fünf-Kräfte-Analyse sowie Fallstudien sind einige der Hinweise, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Auch die Präsenz und Verfügbarkeit europäischer Marken und die Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken, die Auswirkungen inländischer Zölle und Handelsrouten werden bei der Bereitstellung von Prognoseanalysen der Länderdaten berücksichtigt.

Wettbewerbsumfeld und Marktanteilsanalyse für Non-Hodgkin-Lymphom-Diagnostik in Europa

Die Wettbewerbslandschaft des europäischen Marktes für Non-Hodgkin-Lymphomdiagnostik liefert Einzelheiten zu den Wettbewerbern. Zu den Details gehören Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, Präsenz in Europa, Produktionsstandorte und -anlagen, Produktionskapazitäten, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktbreite und -umfang sowie Anwendungsdominanz. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus der Unternehmen auf den Markt für Non-Hodgkin-Lymphomdiagnostik.

Zu den wichtigsten Akteuren auf dem Markt zählen unter anderem CANON MEDICAL SYSTEMS CORPORATION, Koninklijke Philips NV, Siemens Healthcare GmbH, Danaher., Bio-Rad Laboratories, Inc., General Electric Company, Sysmex Corporation, Grail, F. Hoffmann-La Roche, Neusoft Corporation, Agilent Technologies, Inc., NeoGenomics Laboratories, Hologic, Inc, Integrated DNA Technologies, Inc., CENTOGENE NV, Merit Medical Systems, Invitae Corporation, PerkinElmer Inc., QIAGEN und GeneDx, LLC.

SKU-69983

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Klicken Sie auf das Bild, um es zu vergrößern

Interaktives Datenanalyse-Dashboard
Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
Zugriff für Research-Analysten für Anpassungen und Abfragen
Konkurrenzanalyse mit interaktivem Dashboard
Aktuelle Nachrichten, Updates und Trendanalyse
Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung

Demo anfordern

Inhaltsverzeichnis

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S 5 FORCES

5 INDUSTRY INSIGHTS

6 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, REGULATIONS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASED GROWTH IN PREVALENCE OF NON-HODGKIN LYMPHOMA

7.1.2 INCREASE IN AWARENESS REGARDING NON-HODGKIN LYMPHOMA

7.1.3 ADVANCEMENT IN ARTIFICIAL INTELLIGENCE IN DIAGNOSIS OF NON-HODGKIN LYMPHOMA

7.1.4 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UP

7.2 RESTRAINTS

7.2.1 LACK OF AVAILABILITY OF TRAINED AND SKILLED MEDICAL PROFESSIONALS

7.2.2 STRINGENT REGULATIONS AND GUIDELINES FOR DIFFERENT TREATMENTS AND DIAGNOSIS

7.3 OPPORTUNITIES

7.3.1 TECHNICAL ADVANCEMENTS IN CANCER DIAGNOSIS

7.3.2 INCREASING HEALTHCARE EXPENDITURE IN CANCER R&D

7.3.3 GROWING INITIATIVES BY GOVERNMENT AND KEY PLAYERS

7.4 CHALLENGES

7.4.1 LACK OF EARLY DIAGNOSTIC AWARENESS AMONG PEOPLE

7.4.2 HIGH DIAGNOSTIC COST AND FEAR OF TREATMENT

7.4.3 COMMON MISDIAGNOSIS OF NON-HODGKIN LYMPHOMA (NHL)

8 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TEST TYPE

8.1 OVERVIEW

8.2 IMAGING

8.2.1 COMPUTED TOMOGRAPHY (CT)

8.2.2 CHEST X-RAY

8.2.3 MAGNETIC RESONANCE IMAGING (MRI)

8.2.4 ULTRASOUND

8.2.5 POSITRON EMISSION TOMOGRAPHY (PET)

8.3 BIOPSY

8.3.1 EXCISIONAL OR INCISIONAL BIOPSY

8.3.2 CORE NEEDLE BIOPSY

8.4 IMMUNOHISTOCHEMISTRY

8.5 BIOMARKER TEST

8.5.1 BETA 2-M

8.5.2 LDH

8.5.3 CA-125

8.5.4 TP53

8.5.5 NPM1

8.5.6 OTHERS

8.6 GENETIC TEST

8.7 CYTOGENETICS

8.8 LUMBAR PUNCTURE (SPINAL TAP)

8.9 BLOOD TEST

8.1 CYTOCHEMISTRY

8.11 OTHERS

9 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TUMOR TYPE

9.1 OVERVIEW

9.2 AGGRESSIVE LYMPHOMAS

9.2.1 DIFFUSE LARGE B CELL LYMPHOMA

9.2.1.1 INSTRUMENT BASED PRODUCTS

9.2.1.2 PLATFORM BASED PRODUCTS

9.2.1.3 KITS AND REAGENTS

9.2.1.4 OTHER CONSUMABLES

9.2.2 ANAPLASTIC LARGE-CELL LYMPHOMA

9.2.2.1 INSTRUMENT BASED PRODUCTS

9.2.2.2 PLATFORM BASED PRODUCTS

9.2.2.3 KITS AND REAGENTS

9.2.2.4 OTHER CONSUMABLES

9.2.3 MANTLE CELL LYMPHOMA

9.2.3.1 INSTRUMENT BASED PRODUCTS

9.2.3.2 PLATFORM BASED PRODUCTS

9.2.3.3 KITS AND REAGENTS

9.2.3.4 OTHER CONSUMABLES

9.2.4 PERIPHERAL T-CELL LYMPHOMA

9.2.4.1 INSTRUMENT BASED PRODUCTS

9.2.4.2 PLATFORM BASED PRODUCTS

9.2.4.3 KITS AND REAGENTS

9.2.4.4 OTHER CONSUMABLES

9.2.5 LYMPHOBLASTIC LYMPHOMA

9.2.5.1 INSTRUMENT BASED PRODUCTS

9.2.5.2 PLATFORM BASED PRODUCTS

9.2.5.3 KITS AND REAGENTS

9.2.5.4 OTHER CONSUMABLES

9.2.6 BURKITT LYMPHOMA

9.2.6.1 INSTRUMENT BASED PRODUCTS

9.2.6.2 PLATFORM BASED PRODUCTS

9.2.6.3 KITS AND REAGENTS

9.2.6.4 OTHER CONSUMABLES

9.3 INDOLENT LYMPHOMAS

9.3.1 FOLLICULAR LYMPHOMA

9.3.1.1 INSTRUMENT BASED PRODUCTS

9.3.1.2 PLATFORM BASED PRODUCTS

9.3.1.3 KITS AND REAGENTS

9.3.1.4 OTHER CONSUMABLES

9.3.2 CUTANEOUS T-CELL LYMPHOMA

9.3.2.1 INSTRUMENT BASED PRODUCTS

9.3.2.2 PLATFORM BASED PRODUCTS

9.3.2.3 KITS AND REAGENTS

9.3.2.4 OTHER CONSUMABLES

9.3.3 MARGINAL ZONE B CELL LYMPHOMA

9.3.3.1 INSTRUMENT BASED PRODUCTS

9.3.3.2 PLATFORM BASED PRODUCTS

9.3.3.3 KITS AND REAGENTS

9.3.3.4 OTHER CONSUMABLES

9.3.4 LYMPHOPLASMACYTIC LYMPHOMA

9.3.4.1 INSTRUMENT BASED PRODUCTS

9.3.4.2 PLATFORM BASED PRODUCTS

9.3.4.3 KITS AND REAGENTS

9.3.4.4 OTHER CONSUMABLES

9.3.5 SMALL-CELL LYMPHOCYTIC LYMPHOMA

9.3.5.1 INSTRUMENT BASED PRODUCTS

9.3.5.2 PLATFORM BASED PRODUCTS

9.3.5.3 KITS AND REAGENTS

9.3.5.4 OTHER CONSUMABLES

10 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY APPLICATION

10.1 OVERVIEW

10.2 SCREENING

10.2.1 INSTRUMENT BASED PRODUCTS

10.2.2 PLATFORM BASED PRODUCTS

10.2.3 KITS AND REAGENTS

10.2.4 OTHER CONSUMABLES

10.3 DIAGNOSTIC AND PREDICTIVE

10.3.1 INSTRUMENT BASED PRODUCTS

10.3.2 PLATFORM BASED PRODUCTS

10.3.3 KITS AND REAGENTS

10.3.4 OTHER CONSUMABLES

10.4 PROGNOSTIC

10.4.1 INSTRUMENT BASED PRODUCTS

10.4.2 PLATFORM BASED PRODUCTS

10.4.3 KITS AND REAGENTS

10.4.4 OTHER CONSUMABLES

10.5 RESEARCH

10.5.1 INSTRUMENT BASED PRODUCTS

10.5.2 PLATFORM BASED PRODUCTS

10.5.3 KITS AND REAGENTS

10.5.4 OTHER CONSUMABLES

11 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE

11.1 OVERVIEW

11.2 STAGE IV

11.3 STAGE I

11.4 STAGE III

11.5 STAGE II

11.6 STAGE 0

12 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TECHNOLOGY

12.1 OVERVIEW

12.2 FLUORESCENT IN SITU HYBRIDIZATION

12.3 NEXT GENERATION SEQUENCING

12.4 FLUORIMMUNOASSAY

12.5 COMPARATIVE GENOMIC HYBRIDIZATION

12.6 IMMUNOHISTOLOCHEMICAL

12.7 OTHER

13 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY PRODUCT

13.1 OVERVIEW

13.2 INSTRUMENT BASED PRODUCTS

13.2.1 IMAGING

13.2.2 BIOPSY

13.3 PLATFORM BASED PRODUCTS

13.3.1 NEXT-GENERATION SEQUENCING

13.3.2 MICROARRAYS

13.3.3 PCR

13.3.4 OTHERS

13.4 KITS AND REAGENTS

13.4.1 NON-HODGKIN LYMPHOMA PANELS

13.4.2 IMMUNOHISTOCHEMISTRY STAINS

13.4.3 OTHERS

13.5 OTHER CONSUMABLES

14 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 DIAGNOSTIC CENTERS

14.4 CANCER RESEARCH CENTERS

14.5 ACADEMIC INSTITUTES

14.6 AMBULATORY SURGICAL CENTERS

14.7 OTHERS

15 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDER

15.3 RETAIL SALES

15.4 OTHERS

16 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION

16.1 EUROPE

16.1.1 GERMANY

16.1.2 UNITED KINGDOM

16.1.3 FRANCE

16.1.4 ITALY

16.1.5 SPAIN

16.1.6 RUSSIA

16.1.7 NETHERLANDS

16.1.8 SWITZERLAND

16.1.9 BELGIUM

16.1.10 TURKEY

16.1.11 REST OF EUROPE

17 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: EUROPE

18 SWOT ANALYSIS

19 EUROPE NON-HODKIN LYMPHOMA DIAGNOSTICS MARKET

19.1 CANON MEDICAL SYSTEMS CORPORATION

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 KONINKLIJKE PHILIPS N.V.

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENTS

19.3 SIEMENS HEALTHCARE GMBH

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 DANAHER.

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENTS

19.5 BIO-RAD LABORATORIES, INC.

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.6 AGILENT TECHNOLOGIES, INC.

19.6.1 COMPANY PROFILE

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENT

19.7 CENTOGENE N.V.

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 F. HOFFMANN- LA ROCHE LTD

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENTS

19.9 GENERAL ELECTRIC COMPANY

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENTS

19.1 GENEDX, LLC

19.10.1 COMPANY SNAPSHOT

19.10.2 PRODUCT PORTFOLIO

19.10.3 RECENT DEVELOPMENT

19.11 GRAIL

19.11.1 COMPANY PROFILE

19.11.2 PRODUCT PORTFOLIO

19.11.3 RECENT DEVELOPMENT

19.12 HOLOGIC INC.

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENT

19.13 INVITAE CORPORATION

19.13.1 COMPANY PROFILE

19.13.2 REVENUE ANALYSIS

19.13.3 PRODUCT PORTFOLIO

19.13.4 RECENT DEVELOPMENT

19.14 NEUSOFT CORPORATION

19.14.1 COMPANY SNAPSHOT

19.14.2 REVENUE ANALYSIS

19.14.3 PRODUCT PORTFOLIO

19.14.4 RECENT DEVELOPMENT

19.15 NEOGENOMICS LABORATORIES

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENTS

19.16 PERKINELMER INC

19.16.1 COMPANY PROFILE

19.16.2 REVENUE ANALYSIS

19.16.3 PRODUCT PORTFOLIO

19.16.4 RECENT DEVELOPMENT

19.17 QIAGEN

19.17.1 COMPANY SNAPSHOT

19.17.2 REVENUE ANALYSIS

19.17.3 PRODUCT PORTFOLIO

19.17.4 RECENT DEVELOPMENT

19.18 SYSMEX CORPORATION

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

Tabellenverzeichnis

TABLE 1 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 2 EUROPE IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 3 EUROPE IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 4 EUROPE BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 EUROPE BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 6 EUROPE IMMUNOHISTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 7 EUROPE BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 EUROPE BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 9 EUROPE GENETIC TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 EUROPE CYTOGENETICS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 11 EUROPE LUMBAR PUNCTURE (SPINAL TAP) IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 EUROPE BLOOD TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 EUROPE CYTOCHEMISTRY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 EUROPE OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 16 EUROPE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 EUROPE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 18 EUROPE DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 19 EUROPE ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 20 EUROPE MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 21 EUROPE PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 22 EUROPE LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 23 EUROPE BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 24 EUROPE INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 EUROPE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 26 EUROPE FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 27 EUROPE CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 28 EUROPE MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 29 EUROPE LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 30 EUROPE SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 31 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 32 EUROPE SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 EUROPE SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 34 EUROPE DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 EUROPE DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 36 EUROPE PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 EUROPE PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 38 EUROPE RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 EUROPE RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 40 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 41 EUROPE STAGE IV IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 EUROPE STAGE I IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 EUROPE STAGE III IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 EUROPE STAGE II IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION

TABLE 45 EUROPE STAGE 0 IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 47 EUROPE FLUORESCENT IN SITU HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 48 EUROPE NEXT GENERATION SEQUENCING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 49 EUROPE FLUORIMMUNOASSAY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 EUROPE COMPARATIVE GENOMIC HYBRIDIZATION IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 51 EUROPE IMMUNOHISTOCHEMICAL IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 52 EUROPE OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 53 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 54 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 55 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 56 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 57 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 58 EUROPE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 59 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 60 EUROPE OTHER CONSUMABLES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION))

TABLE 61 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 62 EUROPE HOSPITALS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 63 EUROPE DIAGNOSTIC CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 64 EUROPE CANCER RESEARCH CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 65 EUROPE ACADEMIC INSTITUTES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 66 EUROPE AMBULATORY SURGICAL CENTERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 67 EUROPE OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 68 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 69 EUROPE DIRECT TENDER IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 70 EUROPE RETAIL SALES IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 71 EUROPE OTHERS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 72 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 73 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 74 EUROPE IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 75 EUROPE BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 76 EUROPE BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 77 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 78 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 79 EUROPE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 80 EUROPE DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 81 EUROPE ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 82 EUROPE MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 83 EUROPE PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 84 EUROPE LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 85 EUROPE BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 86 EUROPE INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 87 EUROPE FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 88 EUROPE CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 89 EUROPE MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 90 EUROPE LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 91 EUROPE SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 92 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 93 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 94 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 95 EUROPE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 96 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 97 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 98 EUROPE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 99 EUROPE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 100 EUROPE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 101 EUROPE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 102 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 103 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 104 EUROPE SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 105 EUROPE DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 106 EUROPE PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 107 EUROPE RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 108 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 109 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 110 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 111 GERMANY IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 112 GERMANY BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 113 GERMANY BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 114 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 115 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 116 GERMANY AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 117 GERMANY DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 118 GERMANY ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 119 GERMANY MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 120 GERMANY PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 121 GERMANY LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 122 GERMANY BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 123 GERMANY INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 124 GERMANY FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 125 GERMANY CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 126 GERMANY MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 127 GERMANY LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 128 GERMANY SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 129 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 130 GERMANY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 131 GERMANY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 132 GERMANY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 133 GERMANY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 134 GERMANY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 135 GERMANY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 136 GERMANY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 137 GERMANY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 138 GERMANY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 139 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 140 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 141 GERMANY SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 142 GERMANY DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 143 GERMANY PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 144 GERMANY RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 145 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 146 GERMANY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 147 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 148 UNITED KINGDOM IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 149 UNITED KINGDOM BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 150 UNITED KINGDOM BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 151 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 152 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 153 UNITED KINGDOM AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 154 UNITED KINGDOM DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 155 UNITED KINGDOM ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 156 UNITED KINGDOM MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 157 UNITED KINGDOM PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 158 UNITED KINGDOM LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 159 UNITED KINGDOM BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 160 UNITED KINGDOM INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 161 UNITED KINGDOM FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 162 UNITED KINGDOM CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 163 UNITED KINGDOM MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 164 UNITED KINGDOM LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 165 UNITED KINGDOM SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 166 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 167 UNITED KINGDOM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 168 UNITED KINGDOM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 169 UNITED KINGDOM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 170 UNITED KINGDOM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 171 UNITED KINGDOM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 172 UNITED KINGDOM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 173 UNITED KINGDOM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 174 UNITED KINGDOM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 175 UNITED KINGDOM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 176 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 177 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 178 UNITED KINGDOM SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 179 UNITED KINGDOM DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 180 UNITED KINGDOM PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 181 UNITED KINGDOM RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 182 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 183 UNITED KINGDOM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 184 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 185 FRANCE IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 186 FRANCE BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 187 FRANCE BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 188 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 189 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 190 FRANCE AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 191 FRANCE DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 192 FRANCE ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 193 FRANCE MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 194 FRANCE PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 195 FRANCE LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 196 FRANCE BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 197 FRANCE INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 198 FRANCE FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 199 FRANCE CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 200 FRANCE MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 201 FRANCE LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 202 FRANCE SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 203 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 204 FRANCE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 205 FRANCE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 206 FRANCE INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 207 FRANCE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 208 FRANCE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 209 FRANCE PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 210 FRANCE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 211 FRANCE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 212 FRANCE KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 213 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 214 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 215 FRANCE SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 216 FRANCE DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 217 FRANCE PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 218 FRANCE RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 219 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 220 FRANCE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 221 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 222 ITALY IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 223 ITALY BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 224 ITALY BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 225 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 226 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 227 ITALY AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 228 ITALY DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 229 ITALY ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 230 ITALY MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 231 ITALY PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 232 ITALY LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 233 ITALY BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 234 ITALY INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 235 ITALY FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 236 ITALY CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 237 ITALY MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 238 ITALY LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 239 ITALY SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 240 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 241 ITALY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 242 ITALY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 243 ITALY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 244 ITALY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 245 ITALY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 246 ITALY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 247 ITALY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 248 ITALY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 249 ITALY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 250 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 251 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 252 ITALY SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 253 ITALY DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 254 ITALY PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 255 ITALY RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 256 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 257 ITALY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 258 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 259 SPAIN IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 260 SPAIN BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 261 SPAIN BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 262 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 263 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 264 SPAIN AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 265 SPAIN DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 266 SPAIN ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 267 SPAIN MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 268 SPAIN PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 269 SPAIN LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 270 SPAIN BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 271 SPAIN INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 272 SPAIN FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 273 SPAIN CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 274 SPAIN MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 275 SPAIN LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 276 SPAIN SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 277 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 278 SPAIN INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 279 SPAIN INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 280 SPAIN INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 281 SPAIN PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 282 SPAIN PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 283 SPAIN PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 284 SPAIN KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 285 SPAIN KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 286 SPAIN KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 287 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 288 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 289 SPAIN SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 290 SPAIN DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 291 SPAIN PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 292 SPAIN RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 293 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 294 SPAIN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 295 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 296 RUSSIA IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 297 RUSSIA BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 298 RUSSIA BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 299 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 300 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 301 RUSSIA AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 302 RUSSIA DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 303 RUSSIA ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 304 RUSSIA MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 305 RUSSIA PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 306 RUSSIA LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 307 RUSSIA BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 308 RUSSIA INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 309 RUSSIA FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 310 RUSSIA CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 311 RUSSIA MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 312 RUSSIA LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 313 RUSSIA SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 314 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 315 RUSSIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 316 RUSSIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 317 RUSSIA INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 318 RUSSIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 319 RUSSIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 320 RUSSIA PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 321 RUSSIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 322 RUSSIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 323 RUSSIA KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 324 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 325 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 326 RUSSIA SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 327 RUSSIA DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 328 RUSSIA PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 329 RUSSIA RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 330 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 331 RUSSIA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 332 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 333 NETHERLANDS IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 334 NETHERLANDS BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 335 NETHERLANDS BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 336 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 337 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 338 NETHERLANDS AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 339 NETHERLANDS DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 340 NETHERLANDS ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 341 NETHERLANDS MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 342 NETHERLANDS PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 343 NETHERLANDS LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 344 NETHERLANDS BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 345 NETHERLANDS INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 346 NETHERLANDS FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 347 NETHERLANDS CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 348 NETHERLANDS MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 349 NETHERLANDS LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 350 NETHERLANDS SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 351 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 352 NETHERLANDS INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 353 NETHERLANDS INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 354 NETHERLANDS INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 355 NETHERLANDS PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 356 NETHERLANDS PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 357 NETHERLANDS PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 358 NETHERLANDS KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 359 NETHERLANDS KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 360 NETHERLANDS KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 361 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 362 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 363 NETHERLANDS SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 364 NETHERLANDS DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 365 NETHERLANDS PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 366 NETHERLANDS RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 367 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 368 NETHERLANDS NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 369 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 370 SWITZERLAND IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 371 SWITZERLAND BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 372 SWITZERLAND BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 373 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 374 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 375 SWITZERLAND AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 376 SWITZERLAND DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 377 SWITZERLAND ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 378 SWITZERLAND MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 379 SWITZERLAND PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 380 SWITZERLAND LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 381 SWITZERLAND BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 382 SWITZERLAND INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 383 SWITZERLAND FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 384 SWITZERLAND CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 385 SWITZERLAND MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 386 SWITZERLAND LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 387 SWITZERLAND SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 388 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 389 SWITZERLAND INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 390 SWITZERLAND INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 391 SWITZERLAND INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 392 SWITZERLAND PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 393 SWITZERLAND PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 394 SWITZERLAND PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 395 SWITZERLAND KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 396 SWITZERLAND KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 397 SWITZERLAND KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 398 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 399 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 400 SWITZERLAND SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 401 SWITZERLAND DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 402 SWITZERLAND PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 403 SWITZERLAND RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 404 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 405 SWITZERLAND NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 406 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 407 BELGIUM IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 408 BELGIUM BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 409 BELGIUM BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 410 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 411 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 412 BELGIUM AGGRESSIVE LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 413 BELGIUM DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 414 BELGIUM ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 415 BELGIUM MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 416 BELGIUM PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 417 BELGIUM LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 418 BELGIUM BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 419 BELGIUM INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 420 BELGIUM FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 421 BELGIUM CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 422 BELGIUM MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 423 BELGIUM LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 424 BELGIUM SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 425 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 426 BELGIUM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 427 BELGIUM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 428 BELGIUM INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 429 BELGIUM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 430 BELGIUM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 431 BELGIUM PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 432 BELGIUM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 433 BELGIUM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 434 BELGIUM KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 435 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 436 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 437 BELGIUM SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 438 BELGIUM DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 439 BELGIUM PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 440 BELGIUM RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 441 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 442 BELGIUM NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 443 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 444 TURKEY IMAGING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 445 TURKEY BIOPSY IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 446 TURKEY BIOMARKER TEST IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 447 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 448 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 449 TURKEY DIFFUSE LARGE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 450 TURKEY ANAPLASTIC LARGE-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 451 TURKEY MANTLE CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 452 TURKEY PERIPHERAL T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 453 TURKEY LYMPHOBLASTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 454 TURKEY BURKITT LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 455 TURKEY INDOLENT LYMPHOMAS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)

TABLE 456 TURKEY FOLLICULAR LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 457 TURKEY CUTANEOUS T-CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 458 TURKEY MARGINAL ZONE B CELL LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 459 TURKEY LYMPHOPLASMACYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 460 TURKEY SMALL-CELL LYMPHOCYTIC LYMPHOMA IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 461 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 462 TURKEY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 463 TURKEY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 464 TURKEY INSTRUMENT BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 465 TURKEY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 466 TURKEY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 467 TURKEY PLATFORM BASED PRODUCTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 468 TURKEY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 469 TURKEY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 470 TURKEY KITS AND REAGENTS IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)

TABLE 471 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 472 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 473 TURKEY SCREENING IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 474 TURKEY DIAGNOSTIC AND PREDICTIVE IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 475 TURKEY PROGNOSTIC IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 476 TURKEY RESEARCH IN NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 477 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 478 TURKEY NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 479 REST OF EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

Abbildungsverzeichnis

FIGURE 1 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 10 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 12 THE INCREASING PREVALENCE OF NON-HODGKIN LYMPHOMA AND INCREASED RESEARCH & DEVELOPMENT IN NON-HODGKIN LYMPHOMA DIAGNOSTICS ARE DRIVING THE EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 13 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET

FIGURE 15 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2022

FIGURE 16 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)

FIGURE 17 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030)

FIGURE 18 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 19 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2022

FIGURE 20 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, 2023-2030 (USD MILLION)

FIGURE 21 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, CAGR (2023-2030)

FIGURE 22 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TUMOR TYPE, LIFELINE CURVE

FIGURE 23 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2022

FIGURE 24 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, 2023-2030 (USD MILLION)

FIGURE 25 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2023-2030)

FIGURE 26 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 27 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2022

FIGURE 28 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, 2023-2030 (USD MILLION)

FIGURE 29 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, CAGR (2023-2030)

FIGURE 30 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY CANCER STAGE, LIFELINE CURVE

FIGURE 31 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2022

FIGURE 32 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)

FIGURE 33 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, CAGR (2023-2030)

FIGURE 34 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY TECHNOLOGY, LIFELINE CURVE

FIGURE 35 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2022

FIGURE 36 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, 2023-2030 (USD MILLION)

FIGURE 37 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, CAGR (2023-2030)

FIGURE 38 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 39 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2022

FIGURE 40 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 41 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030)

FIGURE 42 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE

FIGURE 43 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 44 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 45 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 46 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 47 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 48 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 49 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 50 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 51 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: TEST TYPE (2023-2030)

FIGURE 52 EUROPE NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

Detaillierte Informationen anzeigen

Forschungsmethodik

Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.

Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.

Anpassung möglich

Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.

Häufig gestellte Fragen

At what growth rate will the market be projected to grow during the forecast period of 2023 to 2030?

The Europe Non-Hodgkin Lymphoma Diagnostics Market is projected to grow at a CAGR of 8.2% during the forecast period by 2030.

Which market segments are covered in this report?

The Asia-Pacific Non-Hodgkin Lymphoma Diagnostics Market is segmented on the basis of test type, cancer stage, tumor type, product, technology, application, end users, and distribution channel.

Who are the major players operating in the market?

The major players in the Europe Non-Hodgkin Lymphoma Diagnostics Market are CANON MEDICAL SYSTEMS CORPORATION (Tochigi Prefecture, Japan), Koninklijke Philips N.V.(Amsterdam, Netherland), Siemens Healthcare GmbH (Erlangen, Germany), Danaher (Washington U.S.), etc.

Which countries data are covered in the report?

The countries covered in the Europe Non-Hodgkin Lymphoma Diagnostics Market are Germany, United Kingdom, France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Turkey and Rest of Europe.

Europäischer Markt für Non-Hodgkin-Lymphom-Diagnostik – Branchentrends und Prognose bis 2030

Europäischer Markt für Non-Hodgkin-Lymphom-Diagnostik – Branchentrends und Prognose bis 2030

Europe Non Hodgkin Lymphoma Diagnostics Market

CAGR : 8.20 %

Europa: Marktanalyse und Einblicke in die Non-Hodgkin-Lymphom-Diagnostik

Europa Non-Hodgkin-Lymphom-Diagnostik Marktdynamik

Auswirkungen von COVID-19 auf den europäischen Markt für Non-Hodgkin-Lymphomdiagnostik

Europa Non-Hodgkin-Lymphom-Diagnostik Marktsegmentierung

Europa: Regionale Analyse/Einblicke zum Non-Hodgkin-Lymphom-Diagnostikmarkt

Wettbewerbsumfeld und Marktanteilsanalyse für Non-Hodgkin-Lymphom-Diagnostik in Europa

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Inhaltsverzeichnis

Tabellenverzeichnis

Abbildungsverzeichnis

Forschungsmethodik

Anpassung möglich

Häufig gestellte Fragen

Berichte

Markteinblicke

Unterstützung

Lösungen

Europäischer Markt für Non-Hodgkin-Lymphom-Diagnostik – Branchentrends und Prognose bis 2030

Europäischer Markt für Non-Hodgkin-Lymphom-Diagnostik – Branchentrends und Prognose bis 2030

Europe Non Hodgkin Lymphoma Diagnostics Market

CAGR : 8.20 %

Europa: Marktanalyse und Einblicke in die Non-Hodgkin-Lymphom-Diagnostik

Europa Non-Hodgkin-Lymphom-Diagnostik Marktdynamik

Auswirkungen von COVID-19 auf den europäischen Markt für Non-Hodgkin-Lymphomdiagnostik

Europa Non-Hodgkin-Lymphom-Diagnostik Marktsegmentierung

Europa: Regionale Analyse/Einblicke zum Non-Hodgkin-Lymphom-Diagnostikmarkt

Wettbewerbsumfeld und Marktanteilsanalyse für Non-Hodgkin-Lymphom-Diagnostik in Europa

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Inhaltsverzeichnis

Tabellenverzeichnis

Abbildungsverzeichnis

Forschungsmethodik

Anpassung möglich

Häufig gestellte Fragen

Verwandte Seiten durchsuchen